Alliance Pharma (APH) Share Price, News & Analysis

Company Overview

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Key Stats

• Today's Range: 42.44 to 43.48
• 50-Day Range: 34.50 to 43.85
• 52-Week Range: 24.55 to 49.45
• Volume: 865,230 shs
• Average Volume: 1.65 million shs
• Market Capitalization: £232.17 million
• P/E Ratio: N/A
• Dividend Yield: 4.66%
• Price Target: GBX 56.50
• Consensus Rating: Moderate Buy

Alliance Pharma Stock Analysis - MarketRank™

Alliance Pharma scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alliance Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Alliance Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Alliance Pharma is -715.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alliance Pharma is -715.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Alliance Pharma has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Alliance Pharma has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for APH.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Alliance Pharma is a leading dividend payer. It pays a dividend yield of 3.75%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Alliance Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for APH.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: N/A

News Sentiment

Alliance Pharma has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alliance Pharma this week, compared to 0 articles on an average week.

Search Interest

Only 16 people have searched for APH on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alliance Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.16% of the stock of Alliance Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.88% of the stock of Alliance Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APH Stock Analysis - Frequently Asked Questions

How have APH shares performed this year?

Alliance Pharma's stock was trading at GBX 40.50 on January 1st, 2024. Since then, APH stock has increased by 6.0% and is now trading at GBX 42.95.
View the best growth stocks for 2024 here.

How do I buy shares of Alliance Pharma?

Shares of APH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Alliance Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alliance Pharma investors own include RPC Group (RPC), American Airlines Group (AAL), BlackBerry (BB), Editas Medicine (EDIT), 1-800-FLOWERS.COM (FLWS), Air Canada (AC) and Ally Financial (ALLY).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Electronic Equipment
• Current Symbol: LON:APH
• CUSIP: N/A
• CIK: N/A
• Web: www.alliancepharma.co.uk
• Phone: +44-1249-466966
• Fax: N/A
• Employees: 91,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 56.50
• High Stock Price Target: GBX 60
• Low Stock Price Target: GBX 53
• Potential Upside/Downside: +31.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 7.74
• P/E Growth: 1.04
• Net Income: £-33,140,000.00
• Net Margins: -18.34%
• Pretax Margin: N/A
• Return on Equity: -13.71%
• Return on Assets: 5.76%

Debt

• Debt-to-Equity Ratio: 53.89
• Current Ratio: 2.57
• Quick Ratio: 1.42

Sales & Book Value

• Annual Sales: £180.68 million
• Price / Sales: 1.29
• Cash Flow: GBX 5.46 per share
• Price / Cash Flow: 7.87
• Book Value: GBX 40 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 540,570,000
• Free Float: N/A
• Market Cap: £232.17 million
• Optionable: Not Optionable
• Beta: 0.67